You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523
SBC: SignalRx Pharmaceuticals Inc. Topic: 102There is an unmet need to inhibit the key cancer promoting transcription factor MYCboth c MYC and MYCNthat act downstream of many cell receptors and signal transcription pathways to activate genes for cancer cell resistance and tumor growthTo datesmall molecule inhibitors of MYC have remained elusiveIn our Phase I STTRCAwe developed a lead compoundSFwhich displays potent orthogonal inhibitory acti ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Jamboxx: Interactive Respiratory Therapy through Music and Gaming
SBC: My Music Machines Inc. Topic: NHLBIProject SummaryAbstract The goal of this project is to develop a novel device for respiratory therapy that uses interactive gaming and music to encourage patient complianceIn order to maintain pulmonary healthmany post operative surgery patients as well as people with quadriplegia and other spinal cord injurieshigh level motor neuron diseases such as amyotrophic lateral sclerosisALSand multiple sc ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment
SBC: BIOVINC, LLC Topic: NIDCRABSTRACT Dental implants are a central part of modern dental practice with the overall market for replacement and reconstruction of teeth expected to reach over $billion in the next several yearsIt is estimated that overmillion people in the United States are missing all of the teeth in one or both of their jaws leading to lower quality of lifeMost of these implants will be successful for long ter ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Peripheral FAAH as a target for novel analgesics
SBC: Anteana Therapeutics Inc Topic: NIDADESCRIPTIONprovided by applicantPain management is a significant unmet medical needAnandamide is an endocannabinoid mediator that plays important roles in the regulation of painPrevious work has shown that endocannabinoid receptors located outside the central nervous systemCNSexert a powerful regulatory control over pain initiationThe biological actions of anandamide are stopped by the enzymefatty ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Augmenting Dual Energy CT for Novel Contrast Agents
SBC: NEXTRAST, INC Topic: 300Project SummaryAbstract Our long term goal is to revolutionize the effectiveness of CT imaging for millions of Americans across a broad range of abdominal diseaseDual energy CTDECTprovides powerful clinical diagnostic potential but remains heavily underutilized despite wide scanner availabilityDECT allows materials to be differentiated based on their relative X ray attenuation at low versus high e ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Assessment of the glucagon receptor blocker REMD-477 on insulin requirements in type 1 diabetes
SBC: REMD BIOTHERAPEUTICS INC. Topic: NIDDKDESCRIPTIONprovided by applicantFast TrackInsulin remains the primaryand often the onlytreatment for typediabetes mellitusT DHowever it is associated with chronic iatrogenic hyperinsulinemiasecondary hyperlipidemiahigher incidence and severity of cardiovascular complicationsand life threatening hypoglycemia eventsA higher mortalityvsdue to cardiovascular complications were reported in insulin trea ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Improvements to Biopharmaceutical Manufacturing
SBC: HocusLocus Inc. Topic: 400PROJECT SUMMARY Over $billion dollarsworth of biological productsincluding antibodiesvaccines and proteinsare produced each yearThis continues to grow worldwide at aboutyearmaking biopharmaceuticals a fairly recession proofgrowing and pro table industryThis shift towards biopharmaceuticals re ects a fundamental shift within the pharmaceutical industryBiomanufacturers are under constant pressure to ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity
SBC: COLORADO RESEARCH PARTNERS LLC Topic: 300Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Science Take-Out Kits for Environmental Health Education
SBC: Science Take-Out, LLC Topic: NIEHSABSTRACT Nearlypercent of death and diseaseworldwideis linked to environmental factorsWHOthereforeit is critical that the general public has a basic understanding of how the environment affects their health and how they might protect themselves against environmental exposuresUnfortunatelyenvironmental health is typically covered minimallyif at allin secondary school classroomsMartinaand there are ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Commercialization of a Novel Therapeutic for Alzheimer's Disease
SBC: CoPlex Therapeutics, LLC Topic: NIAABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production o ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health